BTIG analyst Mark Massaro lowered the firm’s price target on CareDx (CDNA) to $26 from $30 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx price target lowered to $26 from $40 at Craig-Hallum
- CareDx upgraded to Buy from Hold at Nephron Research
- CareDx’s HeartCare Study: A Game Changer in Transplant Monitoring?
- CareDx’s ALAMO Study: A Game Changer in Lung Transplant Surveillance?
- CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance